Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Gulati

Showing results (121-130 of 154) with videos related to

Pageof 16
Sort By:
Journal of the National Cancer Institute|January 12, 2024
Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestryKyung Min Lee, Tyler J Nelson, Alex Bryant, et al.
Plos One|September 9, 2014
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomesRyan R Gordon, Mengchu Wu, Chung-Ying Huang, et al.
Oncotarget|June 9, 2016
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptorDaniel J Coleman, Kathryn Van Hook, Carly J King, et al.
Annals of Internal Medicine|November 29, 2017
Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance CohortsLurdes Y T Inoue, Daniel W Lin, Lisa F Newcomb, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 12, 2026
Prognostic Value of Cycle 1 SPECT SUV<sub>mean</sub> in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, et al.
JCO Precision Oncology|July 17, 2020
<i>CDK12</i>-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint BlockadeMichael T Schweizer, Gavin Ha, Roman Gulati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2019
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate CancerAlexandra N Corella, Ma Victoria Andrea Cabiliza Ordonio, Ilsa Coleman, et al.
Cancer|October 18, 2025
Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survivalKemal Caglar Gogebakan, Zizi Elsisi, Felipe Montano-Campos, et al.
Journal of the National Cancer Institute|September 15, 2023
Prostate cancer screening in African American men: a review of the evidenceKevin H Kensler, Roman Johnson, Faith Morley, et al.
JCO Precision Oncology|April 25, 2024
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to <sup>177</sup>Lu-PSMA-617: A Retrospective Multicenter Cohort StudyRuben Raychaudhuri, George Mo, Abuzar Moradi Tuchayi, et al.
Pageof 16

Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
Journal of the National Cancer Institute|January 12, 2024
Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestryKyung Min Lee, Tyler J Nelson, Alex Bryant, et al.
Plos One|September 9, 2014
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomesRyan R Gordon, Mengchu Wu, Chung-Ying Huang, et al.
Oncotarget|June 9, 2016
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptorDaniel J Coleman, Kathryn Van Hook, Carly J King, et al.
Annals of Internal Medicine|November 29, 2017
Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance CohortsLurdes Y T Inoue, Daniel W Lin, Lisa F Newcomb, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 12, 2026
Prognostic Value of Cycle 1 SPECT SUV<sub>mean</sub> in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, et al.
JCO Precision Oncology|July 17, 2020
<i>CDK12</i>-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint BlockadeMichael T Schweizer, Gavin Ha, Roman Gulati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2019
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate CancerAlexandra N Corella, Ma Victoria Andrea Cabiliza Ordonio, Ilsa Coleman, et al.
Cancer|October 18, 2025
Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survivalKemal Caglar Gogebakan, Zizi Elsisi, Felipe Montano-Campos, et al.
Journal of the National Cancer Institute|September 15, 2023
Prostate cancer screening in African American men: a review of the evidenceKevin H Kensler, Roman Johnson, Faith Morley, et al.
JCO Precision Oncology|April 25, 2024
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to <sup>177</sup>Lu-PSMA-617: A Retrospective Multicenter Cohort StudyRuben Raychaudhuri, George Mo, Abuzar Moradi Tuchayi, et al.
Pageof 16